肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

抗肿瘤药物分级管理专家共识

2021-09-23 中国肿瘤科相关专家小组（统称） 中华肿瘤杂志. 2021,43(09)

肿瘤药物抗肿瘤药物

肿瘤规范化诊疗和抗肿瘤药物的合理使用是医药领域和社会关注的热点,也是医疗质量控制的难点。为了贯彻落实国家卫生健康委员会《抗肿瘤药物临床应用管理办法（试行）》,笔者联合相关专家在广泛调研的基础上,通过采

中文标题：

抗肿瘤药物分级管理专家共识

发布机构：

中国肿瘤科相关专家小组（统称）

发布日期：

2021-09-23

简要介绍：

肿瘤规范化诊疗和抗肿瘤药物的合理使用是医药领域和社会关注的热点,也是医疗质量控制的难点。为了贯彻落实国家卫生健康委员会《抗肿瘤药物临床应用管理办法（试行）》,笔者联合相关专家在广泛调研的基础上,通过采用德尔菲法及多轮专家研讨,对抗肿瘤药物分级管理工作中广泛关注的问题提出推荐建议,形成抗肿瘤药物分级管理指导路线和管理要点的专家共识,为医疗机构做好抗肿瘤药物的分级管理工作提供借鉴。 
 

相关资料下载：
[AttachmentFileName(sort=1, fileName=抗肿瘤药物分级管理专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=fc7851c00219e798, title=抗肿瘤药物分级管理专家共识, enTitle=, guiderFrom=中华肿瘤杂志. 2021,43(09), authorId=0, author=, summary=肿瘤规范化诊疗和抗肿瘤药物的合理使用是医药领域和社会关注的热点,也是医疗质量控制的难点。为了贯彻落实国家卫生健康委员会《抗肿瘤药物临床应用管理办法（试行）》,笔者联合相关专家在广泛调研的基础上,通过采, cover=https://img.medsci.cn/2021929/1632926066830_2020535.jpg, journalId=0, articlesId=null, associationId=747, associationName=中国肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Thu Sep 23 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="row"><span id="ChDivSummary" class="abstract-text" style="color: #666666;">肿瘤规范化诊疗和抗肿瘤药物的合理使用是医药领域和社会关注的热点,也是医疗质量控制的难点。为了贯彻落实国家卫生健康委员会《抗肿瘤药物临床应用管理办法（试行）》,笔者联合相关专家在广泛调研的基础上,通过采用德尔菲法及多轮专家研讨,对抗肿瘤药物分级管理工作中广泛关注的问题提出推荐建议,形成抗肿瘤药物分级管理指导路线和管理要点的专家共识,为医疗机构做好抗肿瘤药物的分级管理工作提供借鉴。&nbsp;</span></div> <div class="row">&nbsp;</div>, tagList=[TagDto(tagId=3321, tagName=肿瘤药物), TagDto(tagId=6223, tagName=抗肿瘤药物)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=5339, guiderKeyword=抗肿瘤药, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3836, appHits=176, showAppHits=0, pcHits=1336, showPcHits=3658, likes=1, shares=13, comments=5, approvalStatus=1, publishedTime=Wed Sep 29 22:55:37 CST 2021, publishedTimeString=2021-09-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Sep 29 22:34:40 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:43:03 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=抗肿瘤药物分级管理专家共识.pdf)])
抗肿瘤药物分级管理专家共识.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1083382, encodeId=76c41083382e0, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 23 00:24:55 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081682, encodeId=c01010816821d, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Dec 19 03:16:49 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065728, encodeId=39be1065e28c7, content=学习学习学习。。。。。。。。。。。。。。。。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6e5682710, createdName=ms8000000124179642, createdTime=Mon Nov 01 09:53:38 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062808, encodeId=d97c106280809, content=不错，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Oct 22 06:14:37 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062486, encodeId=ba46106248656, content=不错，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Oct 21 08:04:03 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-12-23 一己怀

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1083382, encodeId=76c41083382e0, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 23 00:24:55 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081682, encodeId=c01010816821d, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Dec 19 03:16:49 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065728, encodeId=39be1065e28c7, content=学习学习学习。。。。。。。。。。。。。。。。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6e5682710, createdName=ms8000000124179642, createdTime=Mon Nov 01 09:53:38 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062808, encodeId=d97c106280809, content=不错，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Oct 22 06:14:37 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062486, encodeId=ba46106248656, content=不错，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Oct 21 08:04:03 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-12-19 一己怀

    好东西，谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1083382, encodeId=76c41083382e0, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 23 00:24:55 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081682, encodeId=c01010816821d, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Dec 19 03:16:49 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065728, encodeId=39be1065e28c7, content=学习学习学习。。。。。。。。。。。。。。。。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6e5682710, createdName=ms8000000124179642, createdTime=Mon Nov 01 09:53:38 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062808, encodeId=d97c106280809, content=不错，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Oct 22 06:14:37 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062486, encodeId=ba46106248656, content=不错，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Oct 21 08:04:03 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-11-01 ms8000000124179642

    学习学习学习。。。。。。。。。。。。。。。。。。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1083382, encodeId=76c41083382e0, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 23 00:24:55 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081682, encodeId=c01010816821d, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Dec 19 03:16:49 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065728, encodeId=39be1065e28c7, content=学习学习学习。。。。。。。。。。。。。。。。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6e5682710, createdName=ms8000000124179642, createdTime=Mon Nov 01 09:53:38 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062808, encodeId=d97c106280809, content=不错，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Oct 22 06:14:37 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062486, encodeId=ba46106248656, content=不错，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Oct 21 08:04:03 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-10-22 仁术2021

    不错，学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1083382, encodeId=76c41083382e0, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 23 00:24:55 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081682, encodeId=c01010816821d, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Dec 19 03:16:49 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065728, encodeId=39be1065e28c7, content=学习学习学习。。。。。。。。。。。。。。。。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6e5682710, createdName=ms8000000124179642, createdTime=Mon Nov 01 09:53:38 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062808, encodeId=d97c106280809, content=不错，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Oct 22 06:14:37 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062486, encodeId=ba46106248656, content=不错，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Oct 21 08:04:03 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-10-21 仁术2021

    不错，学习了。

    0

拓展阅读

单臂临床试验设计用于支持抗肿瘤药上市申请的适用性技术指导原则

国家药品监督管理局药品审评中心（CDE） · 2023-03-14

单臂临床试验用于支持抗肿瘤药上市申请的适用性技术指导原则

国家药品监督管理局药品审评中心（CDE） · 2023-03-14

新型抗肿瘤药物临床应用指导原则（2023年版）

中华人民共和国国家卫生健康委员会 · 2024-01-02